CJC-1295

Plain-English version: Your brain naturally makes a signal called GHRH (growth hormone-releasing hormone) that tells your pituitary gland to release growth hormone. Natural GHRH is destroyed within minutes by an enzyme in your blood, so its effect is brief. CJC-1295 is a redesigned copy of that same signal, rebuilt to resist that enzyme and keep working far longer.

CJC-1295 was developed by ConjuChem Biotechnologies (later Theratechnologies) as an improvement over native GHRH and earlier analogs like sermorelin. The peptide is based on GHRH(1-29) — the first 29 amino acids of GHRH, which is the shortest fragment that still fully activates the GHRH receptor. Four amino-acid substitutions make it resistant to dipeptidyl peptidase IV (DPP-IV), the enzyme that normally chews up circulating GHRH within a couple of minutes.^[1]

The two forms — this is the part that confuses everyone

The name "CJC-1295" is used for two related but genuinely different molecules, and mixing them up is the single biggest source of confusion:

• CJC-1295 with DAC (Drug Affinity Complex): This version adds a small reactive chemical group that forms a permanent (covalent) bond with albumin — the most abundant protein in your blood — right after injection. Because albumin itself circulates for about three weeks, CJC-1295 "piggybacks" on it and stays active for roughly 8 days from a single shot, producing a steady, round-the-clock rise in GH. This is the version that actually went through human trials.^[1][2]
• CJC-1295 without DAC (Modified GRF 1-29, "Mod GRF 1-29"): Same DPP-IV-resistant backbone, but no albumin-binding group. Its half-life is only about 30 minutes — longer than sermorelin's ~10 minutes but far shorter than the DAC form. That short window means it produces a sharp GH pulse and then clears, which more closely imitates the body's natural rhythm.

Credibility note, stated up front: Nearly all the published human and animal data are for the DAC form. The no-DAC / Mod GRF 1-29 version that dominates community protocols has essentially no published clinical trial data of its own — its rationale is extrapolated from GHRH biology, not from a trial that tested it directly. CJC-1295 is not FDA-approved for any use; its Phase 2 development for GH deficiency and HIV-associated fat redistribution was discontinued, and it remains a research-only compound. See Are Peptides Legal? for the full regulatory picture.

Takeaway first: CJC-1295 does not add growth hormone to your body. It amplifies the signal that makes your own pituitary release GH, and it does so by lasting much longer than the natural signal. Here is what the verified research actually shows, and where it stops.

1. It activates the GHRH receptor — just for much longer

CJC-1295 binds the same GHRH receptor on pituitary cells that your natural GHRH uses, triggering the release of growth hormone. GH then travels to the liver and other tissues, where it drives production of IGF-1 (insulin-like growth factor 1) — the downstream hormone responsible for most of GH's tissue-building and repair effects. The engineering trick is durability, not a new target: by resisting DPP-IV and (in the DAC form) latching onto albumin, one dose keeps the GHRH receptor gently stimulated for days instead of minutes.^[1]

2. In humans, it raised GH and IGF-1 — and kept them up for over a week (DAC form)

This is the strongest evidence CJC-1295 has. In a randomized, double-blind, placebo-controlled Phase 1 trial in healthy adults aged 21-61, a single subcutaneous dose of CJC-1295 (DAC) raised mean GH about 2.4-fold at 2 mcg/kg and up to roughly 10-fold at 30 mcg/kg. IGF-1 rose 1.5- to 3-fold and stayed elevated for 9-11 days after just one injection.^[1] Evidence level: human Phase 1, short-term, healthy volunteers.

3. It preserved the natural GH "pulse" pattern (the key mechanism claim)

Growth hormone is normally released in bursts (pulses), and that rhythm matters — constant, flat GH exposure can blunt the body's response over time. A second human study asked whether a long-acting GHRH analog would flatten those pulses. It did not: despite the ~8-day half-life and continuous stimulation, GH pulse frequency and amplitude were preserved, while trough (baseline) GH rose 7.5-fold, mean GH increased about 46%, and IGF-1 rose about 45%.^[2] This is the actual published basis for the widely repeated "pulsatile vs. sustained" framing — and it comes from the DAC form, not the no-DAC form. Evidence level: human.

4. Animal data support once-daily dosing (mice)

In GHRH-knockout mice (animals genetically unable to make their own GHRH), 2 mcg of CJC-1295 given once daily for five weeks normalized body weight and body length, while dosing every 48 or 72 hours worked less well.^[3] This is where the "once-daily" logic originates — but it is a mouse growth model, not human muscle-gain or fat-loss evidence.

5. Biomarker confirmation in humans

To confirm the whole GH/IGF-1 axis was genuinely switched on, researchers gave 11 healthy young men a single CJC-1295 injection and measured their blood proteins a week later. They found measurable, GH-consistent shifts in the serum protein profile (for example, lower apolipoprotein A1 and transthyretin isoforms, higher beta-hemoglobin and albumin fragments), confirming systemic activation of the axis from one dose.^[4] Evidence level: human pharmacodynamic/biomarker study.

What we do NOT know

There is no published human trial of the no-DAC (Mod GRF 1-29) form. There are no human trials measuring actual body-composition outcomes — muscle gained or fat lost — from any form of CJC-1295. And there are no long-term human safety data. Everything above is real, but it is short-term, mechanistic, and mostly in the DAC version.

How to read this section: for each benefit we give the plain-English claim, the mechanism, the population actually studied, the effect, and the limitation. The honest headline is that CJC-1295's hormonal effects (raising GH and IGF-1) are documented in humans, but the downstream physique and performance benefits people actually want are inferred from what GH and IGF-1 do — not measured in CJC-1295 trials.

Raising growth hormone and IGF-1 (the documented benefit)

Claim: reliably increases your own GH and IGF-1 output. Mechanism: long-acting GHRH-receptor stimulation. Population: healthy adults 21-61 (DAC form). Effect: mean GH up ~2.4-fold to ~10-fold depending on dose; IGF-1 up 1.5-3 fold and sustained for 9-11 days; pulse pattern preserved.^[1][2] Limitation: this is the hormone change, not a clinical outcome — the studies did not measure muscle, fat, or performance. Combining with ipamorelin targets a second receptor (the ghrelin/GH-secretagogue receptor) for a larger combined pulse than either alone.

Body composition & muscle growth (mechanistically plausible, not directly trialed)

Claim: may support lean mass and fat loss over time. Mechanism: GH and IGF-1 increase muscle protein synthesis and nitrogen retention and promote lipolysis (fat breakdown). Population: no CJC-1295 body-composition trial exists in humans; the mouse study showed GH-driven normalization of body weight and length.^[3] Effect: inferred from established GH/IGF-1 physiology, supported by the confirmed rise in those hormones. Limitation: no human study has measured muscle gained or fat lost from CJC-1295. Treat physique claims as extrapolation. For related compounds and context, see tesamorelin and peptides for muscle growth.

Sleep quality & recovery

Claim: may deepen sleep and improve overnight recovery. Mechanism: the largest natural GH pulse occurs during deep (slow-wave) sleep; dosing the short-acting form at bedtime is intended to amplify that pulse, and GH drives tissue repair overnight. Population: no dedicated CJC-1295 sleep trial; the pulse-preservation data show the natural rhythm stays intact.^[2] Effect: plausible, widely reported anecdotally, not measured in a controlled CJC-1295 sleep study. Limitation: anecdote and mechanism, not trial evidence.

Anti-aging & the "somatopause" rationale

Claim: may restore more youthful GH levels as they decline with age. Mechanism: GH secretion falls roughly 10-15% per decade after age 30 (somatopause); a GHRH analog aims to push it back up while keeping the pulse pattern. Population: the biomarker study confirmed axis activation in healthy young men.^[4] Effect: documented hormonal activation; the classic anti-aging endpoints (skin, bone density, cognition) were not measured. Limitation: raising a hormone is not the same as reversing aging outcomes — no CJC-1295 trial tested those endpoints. See the anti-aging peptides guide.

The honest bottom line on "benefits"

• The hormone change is real and human-documented — for the DAC form, short-term.^[1][2]
• The physique/performance benefits are inferred from GH/IGF-1 biology, not measured in any CJC-1295 outcome trial.
• The no-DAC form has no trial of its own — its benefits are assumed from GHRH pharmacology.
• Anecdotes are not data. User reports of better sleep, recovery, and leanness are common but uncontrolled.

Read this first: the doses used in published human trials and the doses used in community protocols are not the same thing, and it's important to keep them separate. Human trials used weight-based single or spaced doses of the DAC form in the range of 2-30 mcg/kg.^[1] The fixed "100-200 mcg 2-3x daily" (no-DAC) and "1-2 mg weekly" (DAC) protocols below come from community and clinic practice, not from those studies. We describe them for completeness and harm reduction, not as medical guidance for an unapproved compound.

Community protocols by form (extrapolated, not trial-validated)

Form	Typical dose	Frequency	Timing	Often combined with
CJC-1295 with DAC	1-2 mg	Once weekly	Any time (long half-life)	Usually standalone
CJC-1295 no DAC (Mod GRF 1-29)	100-200 mcg	2-3x daily	Fasted — bedtime primary, post-exercise optional	Ipamorelin 200-300 mcg

Why the two forms are dosed so differently: the DAC form lasts about a week, so a single weekly injection keeps GH elevated the whole time — convenient, but "always on," which is the trade-off (see side effects). The no-DAC form clears in ~30 minutes, so it is dosed multiple times a day, each dose producing a discrete pulse that mimics natural release. The published human evidence for GH elevation is for the DAC form; the no-DAC dosing logic is inferred from GHRH biology.

The standard beginner stack

The most common research starting point is 100 mcg CJC-1295 (no DAC) + 200 mcg ipamorelin, drawn into the same syringe and injected subcutaneously 1-3x daily — before bed (most important, to amplify the nocturnal pulse) and optionally post-workout and/or on waking. The two peptides hit different receptors, so their GH release adds up. See CJC-1295 vs Ipamorelin for how the two differ.

Reconstitution math, with a worked example

CJC-1295 ships as a lyophilized (freeze-dried) powder that must be mixed with bacteriostatic water before use. The core formula:

Concentration (mcg/mL) = vial amount (mcg) ÷ water added (mL)

Worked example (no-DAC, 100 mcg dosing): take a 2 mg (2,000 mcg) vial and add 2 mL of bacteriostatic water. That gives 2,000 ÷ 2 = 1,000 mcg/mL. To draw a 100 mcg dose: 100 ÷ 1,000 = 0.10 mL, which is 10 units on a standard 100-unit insulin syringe.

Worked example (DAC, 1 mg dosing): take a 5 mg (5,000 mcg) vial and add 2 mL of bacteriostatic water. That gives 5,000 ÷ 2 = 2,500 mcg/mL. To draw a 1,000 mcg (1 mg) dose: 1,000 ÷ 2,500 = 0.40 mL, which is 40 units.

Vial	BAC water	Concentration	100 mcg	1 mg
2 mg	2 mL	1,000 mcg/mL	0.10 mL (10 units)	1.0 mL (100 units)
5 mg	2 mL	2,500 mcg/mL	0.04 mL (4 units)	0.40 mL (40 units)

Preparation: wipe the stopper with alcohol, inject the water slowly down the inside wall (not directly onto the powder), swirl gently until dissolved (never shake), and label the vial with the date and concentration. Use the peptide calculator and bacteriostatic water calculator to check volumes, and the reconstitution guide for a full walkthrough.

Timing, cycles, and storage

• Fasting (no-DAC): administer at least ~2 hours after eating. Food — especially carbohydrates — raises insulin and somatostatin, which blunt the GH response.
• Bedtime dose: the most important, because it stacks on top of the natural nocturnal GH pulse.
• Cycle length: community protocols commonly run 8-12 weeks (sometimes up to 16), with 4-8 weeks off between cycles. These durations are convention, not trial-derived.
• Storage: keep lyophilized vials cold and dark; refrigerate reconstituted solution at 2-8°C and use within about 28 days. See the peptide storage guide.

None of the above is a recommendation to self-administer an unapproved compound; it is a description of how research and community doses are structured.

Straight talk: the published Phase 1 human data reported no serious adverse reactions and described CJC-1295 (DAC) as "safe and relatively well tolerated" over the short term.^[1] That is genuinely more than most research peptides can say — but it is short-term, small, and in healthy volunteers. There are no long-term human safety data for either form, and the no-DAC form has no published safety trial of its own. The two forms also carry different risk profiles.

Reported side effects by form

Effect	DAC form	No-DAC (Mod GRF 1-29)	Mechanism
Water retention / facial puffiness	Common	Mild, transient	GH-mediated sodium and fluid retention
Transient flushing / warmth after injection	Common	Common	Vasodilation / histamine release
Tingling / numbness in hands (carpal-tunnel-like)	More common at higher doses	Uncommon	Fluid pressure on peripheral nerves
Injection-site redness or irritation	Common (mild)	Common (mild)	Local response to subcutaneous injection
Increased hunger	Occasional	Occasional (more with ipamorelin)	GH-secretagogue / ghrelin-pathway effects when stacked
Elevated fasting glucose / reduced insulin sensitivity	Greater concern (sustained GH)	Lower concern at standard doses	GH physiologically antagonizes insulin
Joint aches	Reported with sustained dosing	Rare	Fluid retention in joint tissues
Headache	Occasional	Occasional	Usually transient

Why the DAC form deserves extra caution

The DAC form's ~8-day half-life produces constant GH stimulation. Interestingly, the human trial found that GH pulses were still preserved rather than flattened,^[2] which is reassuring — but sustained elevation of GH and IGF-1 is still mechanistically different from short, natural pulses, and it drives the specific concerns below:

• Insulin resistance / higher fasting glucose: GH naturally opposes insulin, so sustained GH elevation can nudge blood sugar up. Note: while this is a well-established property of chronic GH excess, there is no published primary-source figure quantifying a specific insulin-resistance effect size for CJC-1295 itself — treat it as a mechanistic caution, not a measured trial result.
• Sustained IGF-1 elevation: keeping IGF-1 high around the clock is theoretically relevant to cancer risk because IGF-1 is growth-promoting. This is a theoretical concern, not a documented outcome in CJC-1295 users.
• Acromegaly-pattern effects: at supraphysiological doses over long periods, chronic GH excess can cause soft-tissue and skeletal changes. Not reported at standard research doses, but the theoretical ceiling is worth respecting.

A note on the widely-cited "2007 trial death"

You will frequently read online that a participant died in a French CJC-1295 trial around 2007. We want to be precise: no peer-reviewed publication documents this event, and no published data establish any causal link to CJC-1295. Treat it as an unverified, community-sourced claim — not a citable safety finding, and not proof of a specific danger. We mention it only because it circulates so widely that ignoring it would be worse than addressing it honestly.

Contraindications & drug interactions

• Active or recent cancer: GH and IGF-1 are growth-promoting — avoid entirely; discuss with oncology before any consideration.
• Uncontrolled type 2 diabetes or significant insulin resistance: GH worsens glycemic control; optimize glucose management first and monitor closely.
• Active diabetic retinopathy: GH/IGF-1 can worsen it — avoid until treated and stable.
• Pregnancy and breastfeeding: no data — avoid.
• Acromegaly / active GH excess, pituitary tumors, MEN syndromes: contraindicated.
• Severe heart failure: fluid retention may worsen it.
• Interactions: additive effects with insulin/sulfonylureas (monitor glucose), glucocorticoids (additive insulin resistance), and other GH secretagogues such as sermorelin, ipamorelin, and GHRP-2/6 (additive GH elevation — combine only with caution).

What to do if you experience side effects

• Water retention / puffiness: reduce the dose 25-50%; switch from DAC to no-DAC if it persists.
• Numbness / tingling / wrist symptoms: stop — this is the carpal-tunnel pattern; reassess at a lower dose after it resolves.
• Rising fasting glucose: monitor with a home glucometer, reduce the dose, and discontinue if it keeps climbing.
• Vision changes: stop immediately and seek an ophthalmology evaluation.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: CJC-1295 is an unregulated research compound, and with two similarly-named forms on the market, you can easily receive the wrong molecule — DAC when you wanted no-DAC, or vice versa. On top of that, purity and identity vary widely between suppliers. For an unapproved peptide, product quality is arguably a bigger practical risk than the peptide's own pharmacology.

What a credible product should show

• Third-party COA: an independent Certificate of Analysis with HPLC purity (look for ≥98%) and mass-spectrometry identity confirming the expected molecular weight — and confirming whether it is the DAC or no-DAC version you ordered.
• Batch-specific results: the COA should reference the exact lot you're buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected.
• Proper form: lyophilized powder in a sealed, light-protected vial — not a pre-mixed liquid.

Red flags

• No COA, or a COA from the seller instead of an independent lab
• Ambiguity about DAC vs. no-DAC — a serious vendor states this clearly
• Pre-mixed "ready to use" liquid (shorter shelf life, contamination risk)
• Prices far below market, or explicit human-use / medical claims (a sign of a non-compliant vendor)

Legal & regulatory status (2026)

• Not FDA-approved for any use. CJC-1295 has no approved indication and no finished drug product.
• Development discontinued: ConjuChem/Theratechnologies advanced the DAC form to Phase 2 (GH deficiency, HIV-associated lipodystrophy) in the mid-2000s, then discontinued it. As of 2026 there are no active clinical trials.
• Research-only: it is sold strictly as a research compound and is not part of any approved therapy.
• Sports: GH secretagogues are prohibited by anti-doping authorities — competitive athletes should treat CJC-1295 as bannable.

For the complete legal picture, read Are Peptides Legal?

CJC-1295 is usually weighed against its GHRH-analog neighbors and its stacking partner. None of these comparisons rest on head-to-head human trials — they contrast mechanism, half-life, and the available evidence.

CJC-1295 vs. Sermorelin vs. Tesamorelin (all GHRH analogs)

Factor	CJC-1295 (no DAC)	Sermorelin	Tesamorelin
Half-life	~30 min	~10 min	~26-38 min
Approval status	Research only	Was FDA-approved (diagnostic); now compounded	FDA-approved (HIV lipodystrophy)
Human outcome data	Hormone data only (DAC form)	Older clinical data	Strongest — fat-loss trials

See Sermorelin vs CJC-1295 and CJC-1295 vs Tesamorelin.

CJC-1295 vs. Ipamorelin (partners, not rivals)

Ipamorelin is not a GHRH analog — it activates the ghrelin/GH-secretagogue receptor, a completely separate pathway. That's exactly why the two are stacked rather than compared: CJC-1295 sets the GHRH signal while ipamorelin amplifies the pulse. See CJC-1295 vs Ipamorelin.